Table 3.
Adjuvant and neoadjuvant treatment of the groups.
| Systemic therapies | Group 1 | Group 2 | Group 3 | p | |
|---|---|---|---|---|---|
| Neoadjuvant treatment (NAT) | |||||
| No | n (%) | 822 (88.6) | 61 (89.7) | 147 (79.5) | 0.003 |
| Yes | 106 (11.4) | 7 (10.3) | 38 (20.5) | ||
| Response to NAT | |||||
| No | n (%) | 8 (8.8) | 4 (66.7) | 6 (17.6) | NA |
| Partial | 54 (59.3) | 2 (33.3) | 27 (79.4) | ||
| Almost complete | 14 (15.4) | 0 (0) | 1 (2.9) | ||
| Complete | 15 (16.5) | 0 (0) | 0 (0) | ||
| Adjuvant CT | |||||
| No | n (%) | 225 (29.6) | 16 (27.6) | 61 (38.9) | NA |
| Taxane and/or AC | 517 (67.9) | 41 (70.7) | 92 (58.6) | ||
| CMF | 8 (1.1) | 0 (0) | 1 (0.6) | ||
| Other | 11 (1.4) | 1 (1.7) | 3 (1.9) | ||
| GCSF use | |||||
| No | n (%) | 285 (62.9) | 29 (70.7) | 54 (62.1) | 0.588 |
| Yes | 168 (37.1) | 12 (29.3) | 33 (37.9) | ||
| Radiotherapy | |||||
| No | n (%) | 193 (22.6) | 16 (26.7) | 43 (30.9) | 0.088 |
| Yes | 662 (77.4) | 44 (73.3) | 96 (69.1) | ||
| Hormonotherapy | |||||
| No | n (%) | 175 (20.2) | 21 (31.8) | 72 (44.2) | < 0.001 |
| Tmx | 248 (28.7) | 17 (25.8) | 45 (27.6) | ||
| Aromatase Inh | 398 (46.0) | 25 (37.9) | 40 (24.5) | ||
| Switch | 44 (5.1) | 3 (4.5) | 6 (3.7) | ||
NA not available, CT chemotherapy.